ENTROPY NEURODYNAMICS LIMITED — Director's Dealing 2021

Aug 31, 2021

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Exopharm Limited
ABN	78 163 765 991

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Ian E Dixon
Date of last notice	10 February 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Altnia Holdings Pty Ltd (Director and Controller)
Date of change	01 September 2021
No. of securities held prior to change	28,175,294 Fully Paid Ordinary Shares 166,667 Unlisted Performance Rights
Class	Fully Paid Ordinary Shares Unlisted Performance Rights
Number acquired	83,333 Fully Paid Ordinary Shares
Number disposed	83,333 Unlisted Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	28,258,627 Fully Paid Ordinary Shares 83,334 Unlisted Performance Rights

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change 83,333 Unlisted Performance Rights granted Example: on-market trade, off-market trade, exercise of options, issue under the Company’s Performance Rights Plan of securities under dividend reinvestment plan, participation in buyback (the Plan) vested and converted into 83,333 Fully Paid Ordinary Shares in accordance with the terms of the Plan.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [434 x 321] intentionally omitted <==

----- Start of picture text -----

Detail of contract N/A
Nature of interest N/A
Name of registered holder N/A
(if issued securities)
Date of change N/A
No. and class of securities to which N/A
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired N/A
Interest disposed N/A
Value/Consideration N/A
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change N/A
----- End of picture text -----

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date was N/A this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011